Concepedia

Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices

Guru Sonpavde, Menaka Bhor, Daniel Hennessy, Debajyoti Bhowmik, Liji Shen, Leonardo Nicacio, Debra Rembert, Mark Yap, Ian D. Schnadig

Clinical Genitourinary Cancer · 2015 · 48 citations · 21 references

DOIFull text

Open access

Abstract

Administration of 3 agents in the DCA sequence was more optimal for treating mCRPC in this hypothesis-generating study.

References

21

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.4K citations · Full text

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.5K citations · Full text

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.3K citations · Full text

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text